Overall revenue of $3.5M is up 5% year-over-year Quell shipments of 15.6K devices are up 29% year-over-year Quell shipments of 28.7K electrode reorders are up 99% year-over-year Capital structure was simplified with 86% of outstanding warrants retired WALTHAM, Mass.

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 third quarter financial results before the opening of the market on Thursday October 19, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on October 19,

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq:NURO) today announced it will be a presenting company at the 19 th  Annual Rodman & Renshaw Global Investment Conference, sponsored by H. C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017, at Lotte New York

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) today reported that it will present two scientific posters at the upcoming PAINWeek national conference to be held in Las Vegas, NV, September 5-9. Both studies leveraged the Quell ® Health Cloud, which connects with the Quell

WALTHAM, Mass. --(BUSINESS WIRE)-- In recognition of Pain Awareness Month this September, NeuroMetrix, Inc. (Nasdaq: NURO) is partnering with the U.S. Pain Foundation , a nonprofit organization dedicated to serving those who live with pain conditions and their providers, to raise awareness of the

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,731,126. The patent covers novel technology whereby the Quell ® device automatically modulates therapeutic neurostimulation based on the user's

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported an agreement with Fukuda Denshi for DPNCheck ® distribution in Japan . DPNCheck is NeuroMetrix' rapid, accurate, and quantitative point-of-care test to detect diabetic peripheral neuropathy.

BOSTON --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) reported today that it had shipped its 100,000 th  Quell ® wearable device for treatment of chronic pain since commercial launch in mid-2015. Quell device shipments have posted growth in each of the eight sequential quarters that it has

Revenue of $4.3M is up 63% year-over-year Quell device shipments of 20.1K and electrode reorders of 30.7K represent new quarterly highs DPNCheck revenue of $0.8 million is up 78% year-over-year WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 second quarter financial results before the opening of the market on Thursday July 20, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on July 20, 2017 to